1416575-78-4
1416575-78-4
Chemical Structure
Pomalidomide-d4
Synonym(s): CC-4047-d4
- CAS No.: 1416575-78-4
- Formula:C13H7D4N3O4
- Molecular Weight:277.27
IUPAC Name: methyl 2-(1-methoxycyclobutyl)acetate
InChIKey: UVSMNLNDYGZFPF-CQOLUAMGSA-N
SMILES: O=C1N(C2C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)C(C3=C(N)C=CC=C31)=O
Biological Activity: Pomalidomide-d4 (CC-4047-d4) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer[1][2][3][4].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pomalidomide-d4 | 96.38% | Pomalidomide-d4 (CC-4047-d4) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomalidomide (Standard) | 99.72% | Pomalidomide (Standard) (CC-4047 (Standard)) is the analytical standard of Pomalidomide (HY-10984). This product is intended for research and analytical applications. Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomalidomide-13C5 | Pomalidomide-13C5 (CC-4047-13C5) is the 13C-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomalidomide-d3 | 99.0% | Pomalidomide-d3 (CC-4047-d3) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomalidomide-d5 | Pomalidomide-d5 (CC-4047-d5) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomalidomide-15N,13C5 | Pomalidomide-15N,13C5 (CC-4047-15N,13C5) is the 13C, 15N-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pomalidomide | 99.88% | Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 1.00
HY-10984A(S)-Pomalidomide -
Similarity Score 0.85
HY-W586822N-Methylated pomalidomide -
Similarity Score 0.85
HY-W8677044-Me-Thalidomide -
Similarity Score 0.84
HY-W460141Thalidomide 4-chloro -
Similarity Score 0.84
HY-123324Pomalidomide-5-OH -
Similarity Score 0.84
HY-W0235735-Aminothalidomide -
Similarity Score 0.84
HY-W586107Thalidomide-SH -
Similarity Score 0.83
HY-103596Thalidomide-4-OH -
Similarity Score 0.83
HY-W674436(S)-Thalidomide-4-OH -
Explore the MedChemAI to find more analogs
References
- [1]. Tefferi A, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 20;27(27):4563-9.
- [2]. Hoffmann M, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. [Content Brief]
- [3]. Galustian C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer immunology, immunotherapy : CII. 2009 Jul;58(7):1033-45.
- [4]. Verhelle D, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer research. 2007 Jan 15;67(2):746-55.
